Anika Therapeutics, Inc. (NASDAQ:ANIK) Q4 2021 Earnings Conference Call March 8, 2022 5:30 PM ET Company Participants Mark Namaroff – Vice President, Investor Relations, ESG and Corporate Communications Cheryl Blanchard – President and Chief Executive Officer Mike Levitz – Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants Chris Cooley – Stephens Young Li – UBS Jim Sidoti – Sidoti & Company Operator Good evening, ladies and gentlemen, and welcome to Anika's Fourth ...

Anika Therapeutics, Inc. (NASDAQ:ANIK) Q3 2021 Earnings Conference Call November 4, 2021 5:00 PM ET Company Participants Mark Namaroff - Executive Director, IR & Corporate Communications Cheryl Blanchard - President & CEO Mike Levitz - EVP, CFO & Treasurer Conference Call Participants Young Li - UBS Jim Sidoti - Sidoti & Co. Mike Petusky - Barrington Research Operator Good afternoon, ladies and gentlemen, and welcome to Anika's Third Quarter 2021 Earnings Conference Call. Today's conference is being recorde ...

Anika Therapeutics, Inc. (NASDAQ:ANIK) Q2 2021 Earnings Conference Call August 5, 2021 5:00 PM ET Company Participants Mark Namaroff – Executive Director of Investor Relations and Corporate Communications Cheryl Blanchard – President and Chief Executive Officer Mike Levitz – Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants Yong Lee – UBS Jim Sidoti – Sidoti and Company Mike Petusky – Barrington Research Operator Good day, everyone, and welcome to Anika’s Second Qu ...

Company Overview - Anika is a joint preservation company focused on early intervention orthopedic care[5] - The company's 2020 revenue was $130 million, with $95 million in cash and investments as of March 31, 2021[5] - Anika aims to achieve diversified growth with a projected 2024 revenue mix of 64% in OA Pain Management and 30% in Joint Preservation[5] Market Opportunity and Growth Strategy - Anika is expanding its market opportunity from $1 billion to over $8 billion in joint preservation[12] - The company is targeting to double revenue by 2024 with double-digit adjusted EBITDA growth[12] - Anika has established a commercial footprint in over 75 countries[19] Financial Performance and Outlook - Q1 2021 total revenue decreased by 3% to $343 million compared to Q1 2020[34] - Joint Preservation and Restoration revenue increased by 55% to $122 million in Q1 2021[34] - Joint Pain Management revenue decreased by 24% to $193 million in Q1 2021[34] - The company had $946 million in cash and investments as of March 31, 2021[34]